123-90-0

Basic information

• Product Name: Thiomorpholine
• Synonyms: Tetrahydro-2H-1,4-thiazine, Thiamorpholine;Thiomorpholine,97%;Thiomorpholine ,98%;1,4-Thiazinane, Tetrahydro-2H-1,4-thiazine;ThioMorpholine, 97% 5GR;ThioMorpholine 98.0%Min;ThioMorpholine 98%;4-THIOMORPHOLINE
• CAS NO: 123-90-0
• Molecular Formula: C₄H₉NS
• Molecular Weight: 103.19
• EINECS: 204-660-2
• Product Categories: Morpholines & Thiomorpholines;Morpholines & Thiomorpholines;Ring Systems;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Others;S-Containing;Pyrimidines
• Mol File: 123-90-0.mol

Chemical Properties

• Melting Point: 166-168
• Boiling Point: 169 °C(lit.)
• Flash Point: 140 °F
• Appearance: clear colorless to yellow liquid
• Density: 1.026 g/mL at 25 °C(lit.)
• Vapor Pressure: 1.5mmHg at 25°C
• Refractive Index: n20/D 1.538(lit.)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: organic solvents: miscible(lit.)
• PKA: 9.14±0.20(Predicted)
• Water Solubility: Miscible with waterMiscible with water and organic solvents.
• Sensitive: Air Sensitive
• Merck: 14,9300
• BRN: 102550
• CAS DataBase Reference: Thiomorpholine(CAS DataBase Reference)
• NIST Chemistry Reference: Thiomorpholine(123-90-0)
• EPA Substance Registry System: Thiomorpholine(123-90-0)

Safety Data

• Hazard Codes: C,Xi
• Statements: 34-37-36/37/38-R37-R34
• Safety Statements: 26-36/37/39-45-36-S45-S36/37/39-S26
• RIDADR: UN 3267 8/PG 3
• WGK Germany: 3
• F: 10-13-23
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 123-90-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Thiomorpholine is used as an intermediate in the synthesis of various organic compounds, contributing to the development of pharmaceuticals and other chemical products.
Used in Pharmaceutical Industry:
Thiomorpholine is used as an intermediate for blonanserin, a medication used to treat schizophrenia.
Used in Antimicrobial Applications:
In the preparation of pyrrole derivatives, Thiomorpholine acts as an antimycobacterial agent, helping to combat mycobacterial infections.
Used in Hypocholesterolemic Activity:
Thiomorpholine is involved in hypocholesterolemic activity, potentially contributing to the development of treatments for high cholesterol levels.

Purification Methods

Purify it by vacuum distillation. The hydrochloride has m 179o (from isoPrOH or EtOH/Et2O/HCl). [Davies J Chem Soc 306 1920, Beilstein 27 II 4, 2 III/IV 636.]

InChI:InChI=1/C4H9NS/c1-3-6-4-2-5-1/h5H,1-4H2/p+1

Upstream product

• 106-93-4 ethylene dibromide 
• 334-22-5 N,N-bis(chloro-2-ethyl)amine 
• 60-23-1 Cysteamine 
• 64-17-5 ethanol 
• 111-42-2 2,2'-iminobis[ethanol] 
• 1217491-78-5 C₁₄H₁₇N₃OS₂*ClH 
• 1217491-62-7 C₁₄H₁₉N₃O₂S₂ 
• 45695-98-5 thiomorpholinyl dithiocarbamate 
• 124-02-7 diallylamine 
• 505-60-2 bis (2-chloroethyl) sulphide 
• 20196-21-8 3-thiomorpholinone 

Downstream Products

• 211569-62-9 6-(2-ethoxycarbonylvinyl)-5-(isopropylamino-thiomorpholin-1-yl-methyleneamino)-3,4-diphenylthieno[2,3-c]pyridazine 
• 211569-47-0 6-(2-ethoxycarbonylvinyl)-3,4-diphenyl-5-(phenylamino-thiomorpholin-1-yl-methyleneamino)thieno[2,3-c]pyridazine 
• 211569-53-8 6-(2-ethoxycarbonylvinyl)-5-[(4-fluorophenylamino)-(thiomorpholin-1-yl)-methyleneamino]-3,4-diphenylthieno[2,3-c]pyridazine 
• 211569-58-3 6-(2-ethoxycarbonylvinyl)-5-[(4-methoxyphenylamino)-thiomorpholin-1-yl-methyleneamino]-3,4-diphenylthieno[2,3-c]pyridazine 
• 39213-13-3 thiomorpholine 1-oxide 
• 123-93-3 thiodiacetic acid 
• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 270588-65-3 3-(3,5-dimethyl-pyrazol-1-yl)-6-thiomorpholin-4-yl-[1,2,4,5]tetrazine 
• 325733-46-8 1-(thiomorpholin-4'-yl)-2,4-dinitrobenzene 

Related news

Research paperSynthesis and biological evaluation of novel indole-pyrimidine hybrids bearing morpholine and Thiomorpholine (cas 123-90-0) moieties09/24/2019

Based on our previous screening hit compound 1, a series of novel indole-pyrimidine hybrids possessing morpholine or thiomorpholine moiety were synthesized via an efficient one-pot multistep synthetic method. The antiproliferative activities of the synthesized compounds were evaluated in vitro a...detailed

Design, synthesis and primary activity of Thiomorpholine (cas 123-90-0) derivatives as DPP-IV inhibitors09/10/2019

Thirteen thiomorpholine-bearing compounds were designed and synthesized as dipeptidyl peptidase IV (DPP-IV) inhibitors, with natural and non-natural l-amino acids as the starting materials. Their structures were characterized by 1H NMR, 13C NMR and HR-MS. The target compounds were screened for t...detailed

Amides of non-steroidal anti-inflammatory drugs with Thiomorpholine (cas 123-90-0) can yield hypolipidemic agents with improved anti-inflammatory activity09/08/2019

Novel amides of non steroidal anti-inflammatory drugs (NSAIDs), α-lipoic acid and indole-3-acetic acid with thiomorpholine were synthesised by a simple method and at high yields (60–92%). All the NSAID derivatives highly decreased lipidemic indices in the plasma of Triton treated hyperlipidemi...detailed

Relevant articles and documents

Preparation method of thiomorpholine

The invention discloses a preparation method of thiomorpholine. The preparation method includes: adding diethanol amine and triethylamine, and stirring well; adding methane sulfonyl chloride into a mixed solution for reaction to obtain an acylated reaction product; adding the acylated reaction product into a cyclization reaction kettle, and adding sodium sulfide into cyclization to obtain a cyclization product; adding hydrobromic acid of 40-60% in concentration into the cyclization product for hydrolysis; subjecting a hydrolysis solution to freeing, dewatering, reduced pressure distillation, purification and drying sequentially to obtain thiomorpholine. The preparation method is simple in process, low in raw material cost and suitable for industrialization, and thiomorpholine prepared by the method is high in purity.

Preparation and chemical properties of 5-dialkylaminomethylhydantoins and 2-thio-analogues

An efficient procedure for the preparation of 5- dialkylaminomethylhydantoins 3, which are easily obtained from cyclization of the corresponding urea derivatives 2 starting with β-aminoalanines 1, is described. Methylenehydantoin and the corresponding 2-t

Mechanisms of acid decomposition of dithiocarbamates. 5. Piperidyl dithiocarbamate and analogues

(Chemical Equation Presented) In this work, the acid cleavage at 25°C in 20% v/v aqueous ethanol of a series of analogues of piperidine dithiocarbamate X(C2H4)2NCS2 - (X = CH2, CHCH3, NH, NCH3, S, O) was studied. The pH-rate profiles were obtained in the range of Ho -5 and pH 5. They all presented a dumbell shaped curve with a plateau from which the pH-independent first-order rate constant ko (or the specific acid catalysis kH) was calculated, in addition to the acid dissociation constant of the free (pKa) and conjugate acid (pK+) species of the DTC. LFERs of the kinetically determined pKa and pK+ versus pKN (pKa of parent amine) were used to characterize the reactive species and the structure of the transition state of the rate-determining step. For X = CH2, CH3CH the values of kH agree with those of alkDTCs in the strong base region of the Bronsted plot of log kH versus pKN where the transition state is close to a zwitterion formed by intramolecular water-catalyzed S-to-N proton transfer of the dithiocarbamic acid. However, when X = NH, CH3N, O, S, the reactive species is the DTC anion, which is as reactive as an arylDTC, and similarly, the pK+ values correspond to a parent amine that is about 3-4 pK units more basic. The solvent isotope effect indicated that the acid decomposition of these dithiocarbamate anions is specifically catalyzed by a Hydron anchimerically assisted by the heteroatom through a boat conformation.

An annulation reaction for the synthesis of morpholines, thiomorpholines, and piperazines from β-heteroatom amino compounds and vinyl sulfonium salts

(Chemical Equation Presented) Heterocycling: Diphenyl vinyl sulfonium salt 1 acts first as an electrophile, then a base, and then again as an electrophile in this operationally simple, high yielding, one-pot synthesis of pharmacologically important morpholines, thiomorpholines, and piperazines. Compound 1 is an excellent synthon for the 1,2-ethane dication.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

Tetracyclic benzimidazole derivatives and combinatorial libraries thereof

The present invention relates to novel tetracyclic benzimidazole derivative compounds of the following formula: wherein R1to R10have the meanings described in here. The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds.

Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamides

The invention relates to new piperidinyl-substituted pyridyl carboxamides of the general formula (I), wherein the structure element E has meanings (E1) or (E2) and whereby the heterocyclic ring can optionally have a double bond. These substances have especially high cytostatic activities and pronounced immunosuppressive properties which make them suitable for therapeutic treatment in broad tumor spectrum.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.

N-heterocyclic derivatives as NOS inhibitors

N-Heterocyclic derivatives of the formula (I): are described herein, as well as other N-heterocycles, as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.

Inhibitors of protein isoprenyl transferases

Compounds having the formula or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2—, and (i) heterocyclic-L2—; R2 is selected from (a) (b) —C(O)NH—CH(R14)—C(O)OR15, (c) (d) —C(O)NH—CH(R14)—C(O)NHSO2R16 (e) —C(O)NH—CH(R14)-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R14)—C(O)NR17R18; R3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) —L4—N(R5)—L5—, (b) —L4—O—L5—, (c) —L4—S(O)n—L5— (d) —L4-L6—C(W)—N(R5)—L5—, (e) —L4-L6—S(O)m—N(R5)—L5—, (f) —L4—N(R5)—C(W)—L7-L5—, (g) —L4—N(R5)—S(O)p—L7—L5—, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.